Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-Concept and Dose Range-Finding Study of SCH 527123 in Severe Asthma
2008-004119-36Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of navarixin in severe asthma and asthma (4 arms), sponsored by Merck & Co. Primary endpoint: Time to first severe asthma exacerbation. Started Dec 2009; status: terminated.
02
Drugs
navarixin
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on 2008-004119-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004119-36.